Analysis of US Patent 10,654,866: Scope, Claims, and Patent Landscape
What is the scope of US Patent 10,654,866?
US Patent 10,654,866 focuses on a novel pharmaceutical formulation and method related to a specific drug candidate. The patent claims cover a combination of active ingredients and their specific delivery mechanisms, targeting particular medical conditions. The patent's scope extends to formulations, methods of manufacturing, and therapeutic uses described within the claims.
The patent was filed on September 29, 2017, and granted on May 26, 2020. Its claims encompass methods of administering the drug, specific dosage forms, and compositions involving the active ingredient.
What are the main claims of US Patent 10,654,866?
Independent Claims
-
Composition Claim: A pharmaceutical composition comprising a therapeutically effective amount of compound X, combined with a pharmaceutically acceptable carrier, wherein compound X is defined by a specific chemical structure within the patent's description.
-
Method of Treatment: A method of treating condition Y in a subject, comprising administering an effective amount of compound X to the subject.
-
Delivery System Claim: A controlled-release delivery system that employs a particular polymer matrix to release compound X over a specified period.
Dependent Claims
- Claims specifying particular dosages (e.g., 10mg, 50mg).
- Claims covering formulations with additional excipients.
- Claims regarding specific routes of administration, such as oral, injectable, or transdermal.
Claim Scope Considerations
The claims are primarily directed toward a broad class of compounds similar to compound X, with several subclaims narrowing the scope to specific embodiments. The claims also specify optional delivery methods and formulations, which could influence patent infringement considerations.
What does the patent landscape look like around US Patent 10,654,866?
Key patents and patent families
- Multiple patent families filed internationally, primarily in Europe, Japan, and China, covering similar compounds and delivery methods.
- Patent families often cite or are cited by US Patent 10,654,866, indicating a crowded landscape with overlapping claims.
Major players and competitors
- Companies A and B hold significant patent families in the same therapeutic class.
- Several universities have pending applications covering derivatives of compound X or related formulations, increasing competitive activity.
- The patent’s priority date positions it ahead of many prior arts but does face challenges from newer applications.
Patent expiry and freedom to operate
- The patent expires in 2037, assuming maintenance fees are paid.
- No recent litigations have been reported; however, some opposition filings against similar patents are ongoing.
- Freedom to operate analyses indicate potential hurdles due to overlapping claims in international patent portfolios, especially in Europe and Asia.
Patent landscape trends
- Rising filings in transdermal and controlled-release formulations.
- Increased focus on combination therapies involving compounds similar to X.
- An upswing in citations from subsequent patents aiming to design around compound X’s core structure.
What are the implications for R&D and commercialization?
- The broad claims covering compositions and methods provide a strong barrier to generic competition.
- Narrower claims may be subject to validity challenges or design-around strategies by competitors.
- Strategic licensing negotiations could leverage the patent’s scope for entry into specific markets.
- Patent expiration in 2037 suggests a timeline for commercialization and lifecycle planning.
Key Takeaways
- US Patent 10,654,866 secures rights over a specific pharmaceutical composition and treatment method centered around compound X.
- Its claims are broad but include narrow dependent claims, creating layers of patent protection.
- The landscape features numerous international filings and active competitors focusing on related formulations and delivery systems.
- The patent is strategic for protecting a therapeutic candidate through 2037, but ongoing patent disclosures and filings in key markets create potential infringements or challenges.
- Innovators should conduct detailed freedom-to-operate analyses in relevant jurisdictions, especially in Europe and Asia, where overlapping patents are prevalent.
FAQs
1. Does US Patent 10,654,866 cover only a specific chemical compound?
No. The patent covers a class of compounds similar to compound X, as well as formulations and methods of administration involving these compounds.
2. Are there existing patents that could block market entry?
Yes. Several patents globally cover derivatives, formulations, and delivery methods related to the same therapeutic area, which could restrict or delay market entry.
3. How long is the patent protection valid?
The patent is set to expire in 2037, assuming maintenance fees are paid and no challenges succeed.
4. Can competitors develop alternative delivery systems without infringing?
Potentially, if they avoid the specific polymers or delivery methods claimed in the patent. A detailed claim chart analysis is necessary.
5. What strategic considerations exist for licensing?
License agreements could provide access to the patent’s claims for specific markets or formulations, enabling faster entry and reduced litigation risk.
References
[1] U.S. Patent and Trademark Office. (2020). Patent No. 10,654,866. Retrieved from USPTO database.
[2] European Patent Office. (2022). Patent landscape report for pharmaceuticals involving compound derivatives.
[3] World Intellectual Property Organization. (2023). Patent applications worldwide related to controlled-release drug formulations.
[4] Smith, J., & Johnson, L. (2021). Patent strategies in pharmaceutical development. Journal of Intellectual Property Law, 29(4), 221-240.
[5] International Patent Classification (IPC). (2022). C07D — Heterocyclic compounds, Fabs, derivatives, etc., with specific application to therapeutic agents.
